Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3).

Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3).

Item
http://www.wikidata.org/entity/Q39523484
Early repositioning through compound set enrichment analysis: a knowledge-recycling strategy.Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation.Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.Progress towards the development of SH2 domain inhibitors.Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors.Predicting new indications for approved drugs using a proteochemometric method.Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.Fragment informatics and computational fragment-based drug design: an overview and update.STAT3 the oncogene - still eluding therapy?Functional characterization of TRPM7 in nasopharyngeal carcinoma and its knockdown effects on tumorigenesis.The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.Considerations of Protein Subpockets in Fragment-Based Drug Design.Novel 2-Carbonylbenzo[b]thiophene 1,1-Dioxide Derivatives as Potent Inhibitors of STAT3 Signaling Pathway.L61H46 shows potent efficacy against human pancreatic cancer through inhibiting STAT3 pathway.PhenotypicIn VivoScreening to Identify New, Unpredicted Indications for Existing Drugs and Drug CandidatesA new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy
P2860

Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3).

Item
http://www.wikidata.org/entity/Q39523484
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Fragment-based drug design and ...... or of transcription 3 (STAT3).
@en
Fragment-based drug design and ...... le ligand simultaneous docking
@nl
type
label
Fragment-based drug design and ...... or of transcription 3 (STAT3).
@en
Fragment-based drug design and ...... le ligand simultaneous docking
@nl
prefLabel
Fragment-based drug design and ...... or of transcription 3 (STAT3).
@en
Fragment-based drug design and ...... le ligand simultaneous docking
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Fragment-based drug design and ...... or of transcription 3 (STAT3).
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P932